2020 Non-invasive prenatal testing (NIPT) for aneuploidies

Scheme description
Testing of maternal plasma for fetal aneuploidies.
Disorders/Gene target(s)
Common aneuploidies Trisomy 18 Trisomy 13 Trisomy 21 Sex chromosome aneuploidies Fetal sex
Clinical cases
Two or three clinical cases
Testing/analysis
Detection common aneuploidies
Sample type
Maternal plasma
Techniques
Any methodology
Assessment
Submit a clinical report to include: ● Genotyping of results ● Interpretation of the result ● Clerical accuracy 
Eligibility
All laboratories worldwid
Languages
English
ISO17043 Accredited EQA
No
EQA timeline
Sample dispatchSeptember 2020
Testing period6 weeks
Assessment results
Final Summary report
Other information
Collaboration with EMQN
Fee
£375.00
GenQA code
2020NIPTAN
« Return to EQA scheme list
Go to top